Candel to Present Phase I/II CAN-3110 Glioblastoma Trial Data at Summit
Candel’s CSO Dr. Francesca Barone will present Phase I/II trial data on linoserpaturev (CAN-3110) at the 7th Annual Glioblastoma Drug Development Summit in Boston February 17-19. Interim results showed no dose-limiting toxicity and improved median overall survival versus historical controls, and CAN-3110 holds Fast Track and Orphan Drug designations.
1. Summit Presentation Details
Francesca Barone, Candel’s Chief Scientific Officer, will participate in a workshop, conference presentation and panel discussion at the 7th Annual Glioblastoma Drug Development Summit in Boston February 17-19, focusing on biomarker-driven patient stratification and integration of imaging to define response in recurrent high-grade glioma.
2. CAN-3110 Program Overview
Linoserpaturev (CAN-3110) is a first-in-class oncolytic herpes simplex virus-1 immunotherapy designed for dual oncolysis and immune activation; it is being evaluated in a Phase I/II clinical trial for patients with recurrent high-grade glioma.
3. Interim Trial Findings
Interim data from the ongoing trial reported no dose-limiting toxicity and an improved median overall survival compared with historical controls after a single CAN-3110 injection.
4. Regulatory and Collaboration Updates
CAN-3110 has received Fast Track and Orphan Drug designations from the U.S. FDA, and an expansion cohort supported by the Break Through Cancer foundation is now evaluating repeated injections in recurrent glioblastoma.